Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1

The Journal of Pharmacology and Experimental Therapeutics
Sanjay K PandeyA Robert MacLeod

Abstract

Myotonic dystrophy type 1 (DM1) is the most common form of muscular dystrophy in adults. DM1 is caused by an expanded CTG repeat in the 3'-untranslated region of DMPK, the gene encoding dystrophia myotonica protein kinase (DMPK). Antisense oligonucleotides (ASOs) containing 2',4'-constrained ethyl-modified (cEt) residues exhibit a significantly increased RNA binding affinity and in vivo potency relative to those modified with other 2'-chemistries, which we speculated could translate to enhanced activity in extrahepatic tissues, such as muscle. Here, we describe the design and characterization of a cEt gapmer DMPK ASO (ISIS 486178), with potent activity in vitro and in vivo against mouse, monkey, and human DMPK. Systemic delivery of unformulated ISIS 486718 to wild-type mice decreased DMPK mRNA levels by up to 90% in liver and skeletal muscle. Similarly, treatment of either human DMPK transgenic mice or cynomolgus monkeys with ISIS 486178 led to up to 70% inhibition of DMPK in multiple skeletal muscles and ∼50% in cardiac muscle in both species. Importantly, inhibition of DMPK was well tolerated and was not associated with any skeletal muscle or cardiac toxicity. Also interesting was the demonstration that the inhibition of DMPK...Continue Reading

References

Jul 8, 1997·Proceedings of the National Academy of Sciences of the United States of America·B M DavisD E Housman
Aug 26, 1998·Brain : a Journal of Neurology·C E de Die-SmuldersJ P Geraedts
Aug 10, 2000·Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing·C I BerulS Reddy
Mar 28, 2002·Physiological Reviews·Derek J BlakeKay E Davies
Nov 5, 2005·Proceedings of the National Academy of Sciences of the United States of America·Blaine H M MooersJ Andrew Berglund
Dec 28, 2007·The New England Journal of Medicine·Judith C van DeutekomGert-Jan B van Ommen
Jun 21, 2008·The New England Journal of Medicine·William J GrohRobert M Pascuzzi
Jul 18, 2009·Science·Thurman M WheelerCharles A Thornton
Aug 12, 2009·Proceedings of the National Academy of Sciences of the United States of America·Susan A M MuldersDerick G Wansink
Oct 14, 2009·Proceedings of the National Academy of Sciences of the United States of America·M Bryan WarfJ Andrew Berglund
Jan 9, 2010·Annual Review of Pharmacology and Toxicology·C Frank Bennett, Eric E Swayze
Feb 23, 2010·Biochimica Et Biophysica Acta·Hong M Moulton, Jon D Moulton
Mar 25, 2011·The New England Journal of Medicine·Nathalie M GoemansJudith C van Deutekom
Jul 7, 2011·Proceedings of the National Academy of Sciences of the United States of America·Amparo García-LópezRuben D Artero
Mar 1, 2012·Proceedings of the National Academy of Sciences of the United States of America·Johanna E LeeThomas A Cooper
Aug 4, 2012·Nature·Thurman M WheelerCharles A Thornton
Sep 22, 2012·Lancet Neurology·Bjarne Udd, Ralf Krahe
Nov 28, 2012·Disease Models & Mechanisms·Petrica-Adrian PanaiteIbtissam Barakat-Walter
Dec 13, 2012·Expert Opinion on Drug Metabolism & Toxicology·Rosie Z YuRichard S Geary
Jul 17, 2013·Journal of Cardiovascular Translational Research·Richard G LeeRosanne M Crooke
May 7, 2014·Nucleic Acids Research·Jason W HoskinsCharles A Thornton
May 13, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Yinjian ZhouWei Liang

❮ Previous
Next ❯

Citations

Nov 4, 2016·Nature Reviews. Drug Discovery·Masayuki Matsui, David R Corey
Jul 20, 2016·Journal of Medicinal Chemistry·W Brad Wan, Punit P Seth
Aug 16, 2016·Human Molecular Genetics·Samuel T CarrellCharles A Thornton
Feb 27, 2016·PloS One·Juan M Fernandez-CostaRuben Artero
Oct 17, 2017·Nucleic Acids Research·Samuel T CarrellCharles A Thornton
Sep 11, 2017·American Journal of Medical Genetics. Part a·James J DowlingCraig Campbell
Sep 8, 2017·Muscle & Nerve·Robert Boland-FreitasKarl Ng
Sep 19, 2017·Journal of Clinical Pharmacology·A Robert MacLeod, Stanley T Crooke
Jun 22, 2018·Current Treatment Options in Neurology·Ava Y Lin, Leo H Wang
Feb 12, 2017·Disease Models & Mechanisms·Ludovic ArandelDenis Furling
Oct 21, 2018·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Samantha LoRussoW David Arnold
Apr 21, 2019·International Journal of Molecular Sciences·Mila Gugnoni, Alessia Ciarrocchi
Jun 23, 2019·Human Molecular Genetics·Pedro Gonzalez-Alegre
Jun 22, 2019·Expert Review of Clinical Pharmacology·Federica RicciTiziana Mongini
Sep 4, 2019·Journal of Cellular Biochemistry·Muhammad Imran QadirMajid Manzoor
Dec 25, 2019·Nucleic Acid Therapeutics·Melina ChristouNikolaos P Mastroyiannopoulos
Oct 13, 2016·Annual Review of Pharmacology and Toxicology·C Frank BennettRichard S Geary
Mar 18, 2020·Nucleic Acids Research·Alfred E ChappellPunit P Seth
Apr 29, 2020·International Journal of Molecular Sciences·Siran ZhuGracjan Michlewski
May 28, 2019·Nucleic Acids Research·Thazha P PrakashPunit P Seth
Jul 28, 2018·Frontiers in Neurology·Sandra O BrazMário Gomes-Pereira
Nov 14, 2019·International Journal of Molecular Sciences·Arturo López CastelRubén Artero
Jun 2, 2018·Therapeutic Advances in Neurological Disorders·Claudia D Wurster, Albert C Ludolph
Feb 23, 2020·Der Nervenarzt·Diana Lehmann Urban, Ilka Schneider
Nov 9, 2016·Current Treatment Options in Neurology·Cheryl A Smith, Laurie Gutmann
Jan 22, 2021·Molecular Therapy. Nucleic Acids·Ningyan HuThurman M Wheeler
Dec 24, 2020·Nature Communications·Kung-Chi ChangDavid L Spector
Dec 19, 2020·Genomics, Proteomics & Bioinformatics·Monika HillerPietro Spitali
Dec 25, 2017·Trends in Cell Biology·Chunru Lin, Liuqing Yang
Feb 17, 2018·Trends in Molecular Medicine·Gayatri ArunDavid L Spector
Apr 3, 2021·Drug Discovery Today·Marta Pascual-GilabertRuben Artero
Jan 2, 2021·Trends in Molecular Medicine·Kaitlin WeskampRoy Parker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.